DXC Technology quarterly sales came in at $3.386 billion which beat the analyst consensus estimate of $3.366 billion and represents a 5.71% decrease from the same period last year. The company said its revenue performance was primarily driven by declines in Modern Workplace and Cloud and ITO.
Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share.
Take-Two Interactive reported adjusted earnings of $1.21 per share and quarterly sales of $1.399 billion, beating the $1.299 billion analyst consensus estimate. Total Net Bookings decreased 3% to $1.35 billion, as compared to $1.39 billion from the prior year's fiscal fourth quarter.
Applied Materials said second-quarter revenue was flat on a year-over-year basis. The chip equipment company reported total revenue of $6.646 billion which beat the consensus estimate of $6.537 billion, according to Benzinga Pro. Applied Materials reported adjusted earnings of $2.09 per share, beating analyst estimates of $1.99 per share.
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."